What are Myambutol and Biaxin?
Myambutol (ethambutol) is a first-line oral antituberculosis drug that specifically targets actively growing Mycobacterium tuberculosis, while Biaxin (clarithromycin) is a macrolide antibiotic used to treat various bacterial infections including nontuberculous mycobacterial (NTM) infections, respiratory tract infections, and as part of H. pylori eradication regimens. 1, 2
Myambutol (Ethambutol)
Primary Use: Ethambutol is a first-line agent for treating all forms of tuberculosis caused by susceptible organisms 3.
Key Clinical Role:
- Included in initial TB treatment regimens primarily to prevent emergence of rifampin resistance when primary isoniazid resistance may be present 3
- Part of standard 4-drug initial phase regimens (isoniazid, rifampin, pyrazinamide, ethambutol) for drug-susceptible pulmonary TB 3
Dosing:
- Adults: 15-20 mg/kg daily or 50 mg/kg twice weekly 3
- Children: 15-20 mg/kg daily (maximum 1.0 g) or 50 mg/kg twice weekly (maximum 2.5 g) 3
Critical Adverse Effect:
- Retrobulbar neuritis causing decreased visual acuity or red-green color discrimination 3
- Risk is dose-related with minimal risk at 15 mg/kg daily
- Generally not recommended for young children (<5 years) whose visual acuity cannot be monitored, unless resistance to isoniazid or rifampin is suspected 3
Special Populations:
Biaxin (Clarithromycin)
Primary Uses: Clarithromycin is a macrolide antibiotic with multiple indications 2:
For Adults:
- Respiratory infections: pharyngitis/tonsillitis, sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia
- Skin and skin structure infections
- Disseminated Mycobacterium avium complex (MAC) infections
- H. pylori eradication (in combination with amoxicillin and proton pump inhibitors)
For Nontuberculous Mycobacterial Disease:
- Macrolides (clarithromycin or azithromycin) are the cornerstone of MAC pulmonary disease treatment 4
- For noncavitary nodular/bronchiectatic MAC: 3 times weekly macrolide-based regimen suggested 4
- For cavitary or severe MAC disease: daily macrolide-based regimen suggested 4
- Treatment duration: at least 12 months after culture conversion 4
Key Advantage Over Erythromycin:
- Better acid stability and bioavailability
- Twice-daily dosing (vs. four times daily)
- Lower gastrointestinal intolerance
- Greater activity against selected organisms like H. influenzae 5
Critical Caveat for NTM Treatment:
- The most important goal in MAC therapy is preventing macrolide resistance 4
- Always use a 3-drug macrolide-containing regimen (not 2-drug) to prevent resistance development 4
- For M. kansasii: clarithromycin can substitute for isoniazid in combination with rifampin and ethambutol 4
Drug Interactions:
- Rifampin significantly reduces clarithromycin serum levels, which may impact efficacy 6
Resistance Concerns: